Inspiring day at National Academy of Medicine Emerging Leaders forum.

Privileged to be on a panel about innovation and equitable access for antiobesity medications.

And I got to catch up with fellow academics studying FDA regulation of drugs and devices.

Study examines state Medicaid coverage policies for antiobesity medications and their trends in Medicaid reimbursement from 2011 to 2022.

ja.ma/3vSsxQY

New research from Brigham and Women's Hospital researchers analyzes how the availability of costly treatment for patients with hepatitis C with Medicaid changed after coverage restrictions were relaxed. Their findings are published in JAMA Health Forum. buff.ly/49pxApS Ben Rome

Good luck to them. But I’ll believe it when I see it.

These are some of the most widely used drugs in the US. Part D is a competitive marketplace. If some plans try to force patients to use edoxaban, patients can choose a plan that covers apixabsn or rivaroxaban instead.

Use of effective hepatitis C treatments increased substantially after state Medicaid programs eased access restrictions, according to this nonrandomized clinical trial. ja.ma/49sog4H

Study estimates public and private spending on genetically targeted treatments for Duchenne muscular dystrophy during years in which the drugs were marketed without completed confirmatory studies.

ja.ma/3xfa2Xg

Use of effective hepatitis C treatments increased substantially after state Medicaid programs eased access restrictions, according to this nonrandomized clinical trial. ja.ma/49ojANe Program On Regulation, Therapeutics, And Law CHLPI

Maybe Pfizer Inc. should ditch Paxlovid and test if GLP-1 agonists help with Covid symptoms… they seem to work for everything else 🤷🏻